Brandon Scalea

Articles

Bellmunt Addresses Immunotherapy Advances, Challenges in Bladder Cancer

January 8th 2019

Joaquim Bellmunt, MD, PhD, provides insight on how to navigate the complex treatment paradigm of metastatic bladder cancer.

Crossover to Duvelisib Feasible in Patients With CLL

January 8th 2019

Matthew S. Davids, MD, MMSc, discusses the clinical implications of the DUO trial in patients with chronic lymphocytic leukemia.

Lead Researcher Highlights Latest Acalabrutinib MCL Data

January 8th 2019

Michael Wang, MD, discusses the promise of single-agent acalabrutinib in the treatment of patients with relapsed/refractory mantle cell lymphoma.

Shum Sheds Light on Oncogene-Driven NSCLC Treatment Options

January 7th 2019

Elaine Shum, MD, discusses the rapidly evolving treatment options for patients with oncogene-driven non–small cell lung cancer.

Radiotherapy Shows Benefit in Select Patients With Metastatic Prostate Cancer

January 4th 2019

Chris Parker, MD, discusses the clinical implications of STAMPEDE and how radiotherapy fits into the treatment paradigm for these patients.

Differentiating Among EGFR Inhibitors in NSCLC

January 3rd 2019

Chul Kim, MD, MPH, discusses the additions of EGFR inhibitors to the lung cancer armamentarium and how to best select therapy for these patients.

Challenges Remain With Personalized Medicine in CRC

January 2nd 2019

Pashtoon M. Kasi, MD, MBBS, MS, discusses advances and unmet needs in metastatic colorectal cancer.

Study Refines Racial Risk Stratification in Prostate Cancer

January 2nd 2019

Walter Rayford, MD, PhD, MBA, discusses a race-based study in prostate cancer and how these results can drive treatment and diagnostic strategies.

Role of Liquid Biopsies Continues to Evolve in GI Cancers

December 29th 2018

Ryan B. Corcoran, MD, PhD, discusses the clinical utility and benefits of liquid biopsies in gastrointestinal cancers.

Immunotherapy Advances SCLC Treatment Landscape

December 27th 2018

The new standard of care for the frontline treatment of patients with extensive-stage small cell lung cancer should be atezolizumab and chemotherapy, based on results from the IMpower133 trial.

Optimizing Combinations Next Challenge in mRCC

December 20th 2018

Bradley G. Somer, MD, discusses the potential of combination regimens for patients with metastatic renal cell carcinoma.

Brufsky Anticipates Significant Cost Reductions With Biosimilars

December 20th 2018

Adam M. Brufsky, MD, PhD, discusses the impact of biosimilars in the field of oncology and outlined other strategies and steps that can be taken to mitigate cost when treating patients with breast cancer.

Trial Aims to Match Pediatric Patients With More Precise Leukemia Therapy

December 20th 2018

Yana Pikman, MD, discusses the clinical implications of using an approach to match targeted therapy to pediatric patients with leukemia.

Proton Beam RT in Breast Cancer Provides Benefit, But More Research Required

December 19th 2018

Kimberly S. Corbin, MD, sheds light on the use of proton radiation therapy in the breast cancer space and which patients may benefit from this approach.

Choueiri Highlights Advances and Next Steps in RCC

December 18th 2018

Toni K. Choueiri, MD, discusses recent progress in RCC and where future research is heading in the field.

Lead Researcher Discusses Acalabrutinib Plus BR in MCL

December 18th 2018

Tycel J. Phillips, MD, discusses the clinical implications of acalabrutinib plus bendamustine and rituximab for patients with mantle cell lymphoma.

Expert Discusses Lymphedema Treatment and Challenges in Breast Cancer

December 18th 2018

Oscar J. Manrique, MD, discusses the current treatments for patients with lymphedema who have breast cancer and the challenges that remain in this space.

Enzalutamide/Radium-223 Combo Shows Potential in mCRPC

December 14th 2018

Benjamin L. Maughan, MD, PharmD, discusses the activity of the combination of radium-223 and enzalutamide in patients with metastatic castration-resistant prostate cancer.

CARMENA Data Leave Unanswered Questions in mRCC

December 14th 2018

Paul R. Eber, MD, discusses how the findings from CARMENA impact metastatic renal cell carcinoma treatment and what challenges remain.

Markman Outlines Biosimilars and Cost-Effective Oncology Practices

December 14th 2018

Maurie Markman, MD, discusses the evolution of biosimilars and ongoing efforts to make treatments more affordable for patients with cancer.